Osivax and GC Biopharma announced a major partnership to develop a new-generation influenza vaccine. The vaccine is set to combine OVX836 and GC FLU. Osivax secured the rights to advance a combined shot.
Older adults are facing four vaccine decisions this fall, while the national vaccine schedule continues to carry a 2025 date. Flu and pneumonia deaths have dropped for 25 years, but one American age group posted an uptick.